Go to Top
INVENTOR LOGIN

Details

Project TitleHPV Inhibiting Vaginal Moisturizers
Track Code2016-087
Short Description

FDA-approved compounds that show antiviral properties against HPV.

Abstract

These compounds can be used to develop commercially available vaginal moisturizers that effectively inhibit HPV infection and concurrently relieve the symptoms of vaginal dryness.

 
Tagshpv, topical, antimicrobial, antiviral
 
Posted DateAug 1, 2017 11:07 AM

Researcher

Name
Michelle Ozbun
Zurab Surviladze
Andrew Cowan

Manager

Name
Jovan Heusser

Background

The human papillomavirus, known as HPV, is one of the most common sexually transmitted infections in the United States and around the world.  HPV is passed from one person to another by skin-to-skin contact, including sexual contact, and affects both men and women. There are more that 120 of different HPV strains that can affect different parts of the body, 40 of them are sexually transmitted and affect the genitals, mouth or throat. Each year nearly 14 million people are newly infected in the U.S. alone. Resent reports show that the U.S. spends about 4 billion dollars annually on management of HPV-related infections.  There are two prophylactic HPV vaccines (Gardasil and Cervarix) currently licensed in the U.S. for protection against the most common cancer-associated HPV types.  Unfortunately, these vaccines only protect against certain types of HPV strains, are only effective when is administered in teenage or pre-teenage years, and they can be quite expensive and not accessible for women in most underdeveloped countries.

Recent research shows that older women and postmenopausal women are still sexually active, and may be more vulnerable to sexually transmitted diseases than previously suspected. Estrogen decline, caused by a variety of factors, affects many women and can cause vaginal dryness. Unlike vaginal lubricants, vaginal moisturizers are absorbed into the skin and exert their effects by replacing normal vaginal secretions. Moisturizers can be taken regularly for treatment of chronic vaginal dryness and can help in decreasing vaginal dryness symptoms. Development of broad-spectrum antiviral compounds to block the sexual transmission of HPV would have great potential in topical microbicides, such as vaginal moisturizers.

Technology Description

Researchers at the University of New Mexico have discovered FDA-approved compounds that show antiviral properties against HPV.  These compounds can be used to develop commercially available vaginal moisturizers that effectively inhibit HPV infection and concurrently relieve the symptoms of vaginal dryness.

Advantages/Applications

  • Inhibits pre- and post-attachment events of HPV infection
  • Compound is already FDA approved
  • Potential to develop commercially available vaginal moisturizers with new antimicrobial properties against HPV

INQUIRES

STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at amirabal@stc.unm.edu or 505-272-7886.